Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more

Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more

February 21, 2024 12:11 AM UTC

The “gene placement” system from venture-backed Kelonia Therapeutics Inc. has attracted a new pharma partner, as Astellas Pharma Inc. (Tokyo:4503) is paying $40 million up front in a structured deal under which the partners will create in vivo CAR T therapies.

Launched nearly two years ago, Kelonia has developed a platform with which it can use lentiviral particles to deliver genetic cargoes to extrahepatic sites, with selectivity for specific tissues...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article